MedTrace Logo

GRADE-SRM: Genomic Risk Assessment and Decisional Evaluation for Small Renal Masses

NCT03819569 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 265

Last updated 2024-07-03

No results posted yet for this study

Summary

Purpose: The purpose of this study is to evaluate the role of renal mass biopsy on decision-making for patients presenting with clinical T1 kidney tumors. This study also incorporates integrated biomarker study to compare the genomic data obtained through biopsy tissue to genomic information from surgical data.

Conditions

  • Small Renal Mass
  • Kidney Tumor

Interventions

PROCEDURE

Small Renal Mass Biopsy

Subjects will receive a small renal mass biopsy prior to making a treatment decision

OTHER

No Small Renal Mass Biopsy

Subjects will not receive a small renal mass biopsy prior to making a treatment decision

Sponsors & Collaborators

  • UNC Lineberger Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Hung J Tan, MD · UNC Lineberger Comprehensive Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-30
Primary Completion
2024-04-18
Completion
2024-04-18

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03819569 on ClinicalTrials.gov